Share-based Payment Arrangement, Expense of Neumora Therapeutics, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Neumora Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2022 to 30 Sep 2025.
  • Neumora Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $5,980,000, a 40% decline year-over-year.
  • Neumora Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $32,372,000, a 10% decline year-over-year.
  • Neumora Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $39,990,000, a 132% increase from 2023.
  • Neumora Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $17,240,000, a 108% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Neumora Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $32,372,000 $5,980,000 -$3,966,000 -40% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $36,338,000 $7,165,000 -$5,603,000 -44% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $41,941,000 $9,324,000 +$1,951,000 +26% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $39,990,000 $9,903,000 +$3,852,000 +64% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $36,138,000 $9,946,000 +$3,495,000 +54% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $32,643,000 $12,768,000 +$10,225,000 +402% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $22,418,000 $7,373,000 +$5,178,000 +236% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $17,240,000 $6,051,000 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $6,451,000 +$4,350,000 +207% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $2,543,000 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $2,195,000 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q3 2022 $2,101,000 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3

Neumora Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $39,990,000 +$22,750,000 +132% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $17,240,000 +$8,942,000 +108% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $8,298,000 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.